Clinical trial
An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis
NCT04288856 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis
- Lead sponsor
- Biogen
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- April 28, 2020
- Completion date
- May 3, 2022
- Enrollment
- 75 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.